"Better Design Award"-- Creating the Best Design, Achieving a Better Life
GUANGZHOU, China, Dec. 17, 2024 /PRNewswire/ -- On May 22, 2024, the global promotion event of "Better Design Award" (abbreviated as BDA) was held magnificently in Guangzhou, China. BDA is an international comprehensive design competition accessible...
Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial
Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients with Huntington's Disease Volumetric MRI measurement is also approved as exploratory study endpoint BOSTON,...
GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment
YONGIN, South Korea, Nov. 26, 2024 /PRNewswire/ -- GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial with 'GC1130A', an innovative new drug for Sanfillippo syndrome type A...
Tata Power Signs MoU with Asian Development Bank for US$4.25 Billion to Finance Key Clean Energy Power Projects
SINGAPORE, Nov. 21, 2024 /PRNewswire/ -- Tata Power, one of India's leading integrated power companies, and the Asian Development Bank (ADB) have signed a Memorandum of Understanding (MoU) coinciding with the ongoing Climate Conference (COP29) at...